CA2293335A1 - Derives de 9-oxime erythromycine - Google Patents

Derives de 9-oxime erythromycine Download PDF

Info

Publication number
CA2293335A1
CA2293335A1 CA002293335A CA2293335A CA2293335A1 CA 2293335 A1 CA2293335 A1 CA 2293335A1 CA 002293335 A CA002293335 A CA 002293335A CA 2293335 A CA2293335 A CA 2293335A CA 2293335 A1 CA2293335 A1 CA 2293335A1
Authority
CA
Canada
Prior art keywords
carbamate
methyl
deoxo
hydrazo
deoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002293335A
Other languages
English (en)
Inventor
Yong-Jin Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2293335A1 publication Critical patent/CA2293335A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

La présente invention concerne des composés de la formule (I) et leurs sels pharmaceutiquement acceptables, dans laquelle R?1¿, R?2¿, R?6¿ et X sont tels que définis ci-dessus. L'invention se rapporte également à des compositions pharmaceutiques contenant les composés de la formule (I), à des procédés d'utilisation desdits composés dans le traitement des infections bactériennes et des protozooses, et à des procédés de préparation desdits composés.
CA002293335A 1997-06-11 1998-05-15 Derives de 9-oxime erythromycine Abandoned CA2293335A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4934997P 1997-06-11 1997-06-11
US60/049349 1997-06-11
PCT/IB1998/000741 WO1998056800A1 (fr) 1997-06-11 1998-05-15 Derives de 9-oxime erythromycine

Publications (1)

Publication Number Publication Date
CA2293335A1 true CA2293335A1 (fr) 1998-12-17

Family

ID=21959341

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002293335A Abandoned CA2293335A1 (fr) 1997-06-11 1998-05-15 Derives de 9-oxime erythromycine

Country Status (31)

Country Link
EP (1) EP0988308A1 (fr)
JP (1) JP2000513026A (fr)
KR (1) KR20010013660A (fr)
CN (1) CN1259135A (fr)
AP (1) AP9801253A0 (fr)
AR (1) AR012244A1 (fr)
AU (1) AU7226798A (fr)
BG (1) BG103947A (fr)
BR (1) BR9810021A (fr)
CA (1) CA2293335A1 (fr)
CO (1) CO4940506A1 (fr)
CZ (1) CZ9904388A3 (fr)
EA (1) EA199901016A1 (fr)
GT (1) GT199800074A (fr)
HN (1) HN1998000073A (fr)
HR (1) HRP980316A2 (fr)
HU (1) HUP0002252A3 (fr)
ID (1) ID24529A (fr)
IL (1) IL132767A0 (fr)
IS (1) IS5251A (fr)
MA (1) MA26505A1 (fr)
NO (1) NO996108L (fr)
OA (1) OA11225A (fr)
PA (1) PA8451801A1 (fr)
PE (1) PE79899A1 (fr)
PL (1) PL337606A1 (fr)
TN (1) TNSN98083A1 (fr)
TR (1) TR199902995T2 (fr)
TW (1) TW448174B (fr)
WO (1) WO1998056800A1 (fr)
ZA (1) ZA985018B (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HN1998000159A (es) * 1997-10-29 1999-02-09 Monsanto Co Derivados de 9- amino - 3 ceto eritromicina
EP1115732B1 (fr) 1998-09-22 2005-06-29 Pfizer Products Inc. Antibiotiques carbamates et carbazates cetolides
FR2786188B1 (fr) * 1998-11-24 2002-10-31 Hoechst Marion Roussel Inc Nouveaux derives de l'erythromycine, leur procede de preparation et leur applicaion comme medicaments
US6258785B1 (en) 1998-12-02 2001-07-10 Pfizer Inc. Crystalline 9-E-(O-methyl)oxime of 11, 12-dideoxy-3-de(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribohexopyranosyloxy)-6-O-methyl-12,11-(iminocarbonyl-(2-(3-(4-(3-pyridinyl)1H-imadazol-1-yl)propyl)hydrazono))-3-oxoerythromycin
EP1298138B1 (fr) * 1998-12-10 2006-11-02 Pfizer Products Inc. Dérivés anitiobiotiques de Carbamate et de Carbazate Kètolides
US6284732B1 (en) * 1998-12-18 2001-09-04 Bio-Rad Laboratories, Inc. Peptides and peptide analogues designed from HFE protein and their uses in the treatment of iron overload diseases
WO2000063225A2 (fr) * 1999-04-16 2000-10-26 Kosan Biosciences, Inc. Agents anti-infectieux macrolide
TR200103395T2 (tr) 1999-05-24 2002-04-22 Pfizer Products Inc. 13-metil eritromisin türevleri.
DE60005334T2 (de) * 1999-06-07 2004-06-24 Abbott Laboratories, Abbott Park 6-o-carbamat ketolide derivate
ID27331A (id) * 1999-09-29 2001-03-29 Pfizer Prod Inc Pembuatan antibiotik-antibiotik ketolida karbamat
EP1439186A3 (fr) * 1999-12-29 2004-11-03 Pfizer Products Inc. Intermédiaires pour macrolides antibactérielles et procinétiques
EP1114826A3 (fr) * 1999-12-29 2001-10-31 Pfizer Products Inc. Macrolides antibactériennes et prokinétiques
US6946446B2 (en) 2000-02-24 2005-09-20 Abbott Laboratories Anti-infective agents useful against multidrug-resistant strains of bacteria
US6403776B1 (en) 2000-07-05 2002-06-11 Pfizer Inc. Synthesis of carbamate ketolide antibiotics
WO2003090761A1 (fr) * 2002-04-25 2003-11-06 Abbott Laboratories Antibacteriens 9-oxime macrolide
TW200420573A (en) 2002-09-26 2004-10-16 Rib X Pharmaceuticals Inc Bifunctional heterocyclic compounds and methods of making and using same
EP1638549A4 (fr) * 2003-03-10 2011-06-15 Optimer Pharmaceuticals Inc Nouveaux agents antibacteriens
US8202843B2 (en) 2004-02-27 2012-06-19 Rib-X Pharmaceuticals, Inc. Macrocyclic compounds and methods of making and using the same
JP5698979B2 (ja) 2007-10-25 2015-04-08 センプラ ファーマシューティカルズ，インコーポレイテッド マクロライド系抗菌剤の調製プロセス
DK2358379T3 (en) 2008-10-24 2016-03-07 Cempra Pharmaceuticals Inc BIOFORSVAR USING TRIAZOLHOLDIGE macrolides
US9937194B1 (en) 2009-06-12 2018-04-10 Cempra Pharmaceuticals, Inc. Compounds and methods for treating inflammatory diseases
CN102724874B (zh) 2009-09-10 2018-06-01 森普拉制药公司 治疗疟疾、结核病和mac疾病的方法
CN102146085B (zh) * 2010-02-09 2014-03-26 北京理工大学 一种9-肟醚酮内酯衍生物、制备方法及其药物组合物
WO2011119604A1 (fr) 2010-03-22 2011-09-29 Cempra Pharmaceuticals, Inc. Formes cristallines d'un macrolide et leurs utilisations
CN102917708B (zh) 2010-05-20 2015-11-25 森普拉制药公司 制备大环内酯和酮内酯及其中间体的方法
KR20130120458A (ko) 2010-09-10 2013-11-04 셈프라 파마슈티컬스, 인크. 질환을 치료하기 위한 수소결합 형성 플루오로 케토라이드
NZ700182A (en) 2012-03-27 2017-02-24 Cempra Pharmaceuticals Inc Parenteral formulations for administering macrolide antibiotics
CA2905975A1 (fr) 2013-03-14 2014-09-25 Cempra Pharmaceuticals, Inc. Procedes pour traiter des maladies respiratoires et formulations pour la mise en oeuvre de ceux-ci
US9751908B2 (en) 2013-03-15 2017-09-05 Cempra Pharmaceuticals, Inc. Convergent processes for preparing macrolide antibacterial agents

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL99995A (en) * 1990-11-21 1997-11-20 Roussel Uclaf Erythromycin derivatives, their preparation and pharmaceutical compositions containing them
US5527780A (en) * 1992-11-05 1996-06-18 Roussel Uclaf Erythromycin derivatives
FR2718450B1 (fr) * 1994-04-08 1997-01-10 Roussel Uclaf Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments.

Also Published As

Publication number Publication date
PE79899A1 (es) 1999-08-25
JP2000513026A (ja) 2000-10-03
TW448174B (en) 2001-08-01
HUP0002252A2 (hu) 2000-12-28
WO1998056800A1 (fr) 1998-12-17
BG103947A (en) 2000-07-31
AU7226798A (en) 1998-12-30
AP9801253A0 (en) 1999-12-04
EP0988308A1 (fr) 2000-03-29
GT199800074A (es) 1999-11-27
OA11225A (en) 2003-07-17
ZA985018B (en) 1999-12-10
PL337606A1 (en) 2000-08-28
BR9810021A (pt) 2000-09-19
CN1259135A (zh) 2000-07-05
NO996108L (no) 2000-02-10
CO4940506A1 (es) 2000-07-24
HUP0002252A3 (en) 2002-01-28
MA26505A1 (fr) 2004-12-20
IL132767A0 (en) 2001-03-19
ID24529A (id) 2000-07-20
CZ9904388A3 (cs) 2002-10-16
EA199901016A1 (ru) 2000-06-26
HRP980316A2 (en) 1999-04-30
AR012244A1 (es) 2000-09-27
TNSN98083A1 (fr) 2005-03-15
TR199902995T2 (xx) 2000-02-21
IS5251A (is) 1999-11-16
NO996108D0 (no) 1999-12-10
HN1998000073A (es) 1999-01-08
PA8451801A1 (es) 2000-05-24
KR20010013660A (ko) 2001-02-26

Similar Documents

Publication Publication Date Title
EP0988310B1 (fr) Derives de homo-erythromycine -9-deoxo-9a-aza-9aa substitution en position 4
CA2293335A1 (fr) Derives de 9-oxime erythromycine
US6159945A (en) 9-amino-3-keto erythromycin derivatives
CA2293397C (fr) Derives de macrolide substitue en c-4''
US6329345B1 (en) 13-membered azalides and their use as antibiotic agents
EP0984019B1 (fr) C11-carbamates des macrolides antibactériens
EP0992509B1 (fr) Nouveaux dérivés macrolides
US6162794A (en) Erythromycin derivatives
US6248719B1 (en) Tricyclic 3-keto derivatives of 6-O-methylerthromycin
US20020025937A1 (en) 9-oxime erythromycin derivatives
US6498146B1 (en) Erythromycin derivatives
EP0952157B1 (fr) Dérivés 9A, 11B-Déhydro de 9-oxime-3-keto-6-0-méthylérythromycine
MXPA99011494A (en) 9-oxime erythromycin derivatives
EP1437360A2 (fr) C11-carbamates des macrolides antibactériens
MXPA01005055A (en) 13-membered azalides and their use as antibiotic agents
MXPA99011495A (en) 4"-substituted-9-deoxo-9a-aza-9a-homoerythromycin a derivatives

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued